L
Luis Ruiz del Arbol
Researcher at University of Alcalá
Publications - 12
Citations - 2295
Luis Ruiz del Arbol is an academic researcher from University of Alcalá. The author has contributed to research in topics: Cirrhosis & Ascites. The author has an hindex of 11, co-authored 12 publications receiving 2102 citations. Previous affiliations of Luis Ruiz del Arbol include University of Barcelona.
Papers
More filters
Journal ArticleDOI
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Riccardo Lencioni,Josep M. Llovet,Guohong Han,Won Young Tak,Jiamei Yang,Alfredo Guglielmi,Seung Woon Paik,Maria Reig,Do Young Kim,Gar Yang Chau,Angelo Luca,Luis Ruiz del Arbol,Marie Aude Leberre,Woody Niu,Kate Nicholson,Gerold Meinhardt,Jordi Bruix +16 more
TL;DR: Sorafenib plus DEB-TACE was technically feasible, but the combination did not improve TTP in a clinically meaningful manner compared with DEB -TACE alone.
Journal ArticleDOI
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis
Pere Ginès,Juan Uriz,B. Calahorra,Guadalupe Garcia–Tsao,Patrick S. Kamath,Luis Ruiz del Arbol,Ramon Planas,Jaime Bosch,Vicente Arroyo,Juan Rodés +9 more
TL;DR: In patients with refractory ascites, TIPS lowers the rate of ascites recurrence and the risk of developing hepatorenal syndrome, but TIPS does not improve survival and is associated with an increased frequency of severe encephalopathy and higher costs compared with repeated paracentesis plus albumin.
Journal ArticleDOI
Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.
Javier Fernández,Luis Ruiz del Arbol,C. Gómez,Rosa Durández,Regina Serradilla,Carlos Guarner,Ramon Planas,Vicente Arroyo,Miguel Navasa +8 more
TL;DR: Intravenous ceftriaxone is more effective than oral norfloxacin in the prophylaxis of bacterial infections in patients with advanced cirrhosis and hemorrhage.
Journal ArticleDOI
Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial
TL;DR: The V2 receptor antagonist satavaptan improves the control of ascites and increases serum sodium in patients with cirrhosis, ascites, and hyponatremia under diuretic treatment.
Journal ArticleDOI
Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study.
Angels Escorsell,Luis Ruiz del Arbol,Ramon Planas,Agustín Albillos,Rafael Bañares,Paul Calès,Dominique Pateron,B Bernard,Jean-Pierre Vinel,Jaume Bosch +9 more
TL;DR: Terrlipressin may represent a first‐line treatment in acute variceal bleeding until the administration of elective therapy, especially in hospitals where a skilled endoscopist is not available 24 hours a day.